INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near complete and sustained inhibition of the alternative pathway and its tolerability
View HTML
Toggle Summary Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND) application to be submitted in fourth quarter of 2019 BLUE BELL, Pa.
View HTML
Toggle Summary Achillion to Present at the JMP Securities Life Sciences Conference
BLUE BELL, Pa. , June 13, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Brian Di Donato , Chief Financial
View HTML
Toggle Summary Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association
BLUE BELL, Pa. , June 10, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH-4471
View HTML
Toggle Summary Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting
- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa. , May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated
View HTML
Toggle Summary Achillion Granted Twentieth Patent for Factor D Portfolio
USPTO grants composition of matter patent for ACH-5548, Achillion’s 3rd clinical-stage asset BLUE BELL, Pa. , May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families
View HTML
Toggle Summary Achillion Reports First Quarter 2019 Financial Results
- PNH combo Phase 2 trial interim data to be presented May 17, 2019 - - C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 - - Cash and securities of $254 million as of March 31, 2019 - BLUE BELL, Pa.
View HTML
Toggle Summary Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials - - Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa. , April 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa. , March 27, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion to Present at the Barclays Global Healthcare Conference
BLUE BELL, Pa. , March 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
View HTML